CRISPR makes prostate cancer vulnerable to immunotherapy
New CRISPR gene-editing research indicates a method to improve the immune system's ability to detect and target prostate cancer tumors.
7 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 1 news category, from Jun 24, 2026 through Jul 27, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
New CRISPR gene-editing research indicates a method to improve the immune system's ability to detect and target prostate cancer tumors.
Medical experts are highlighting the critical role of early detection and robotic surgery as prostate cancer cases rise beyond metropolitan areas.
A second PSMA PET scan may alter the treatment course for nearly 50% of prostate cancer patients, according to new study data.
A shift in government policy regarding testosterone therapy is sparking a debate over the treatment of age-related hormone decline.
A new blood test, Stockholm3, is outperforming traditional PSA screenings by detecting 90% of aggressive prostate cancer cases.
Thousands of men with prostate cancer can now access high-powered radiotherapy via the NHS to treat early-stage disease more efficiently.
A new multicomponent blood test is outperforming traditional PSA screenings in detecting clinically significant prostate cancer.